Most statin side effects lack evidence, major meta-analysis finds

A Lancet meta-analysis of 19 large randomized trials (over 122,000 participants) finds that most reported statin side effects are not supported by reliable evidence, with real adverse effects being rare (about 1% muscle symptoms; rare rhabdomyolysis; small increases in liver tests and glucose for those near diabetes thresholds). The benefits remain substantial: roughly 25% lower risk of heart attack or stroke and meaningful LDL reductions, with inexpensive generic options (~$40/year). Updated PREVENT-based risk estimates could expand who should start statins, underscoring that fears of side effects should not unduly deter appropriate preventive therapy.